Stanford Advisors


All Publications


  • Unraveling unique features of plasma cell clones in POEMS syndrome by single-cell analysis. JCI insight Isshiki, Y., Oshima, M., Mimura, N., Kayamori, K., Miyamoto-Nagai, Y., Seki, M., Nakajima-Takagi, Y., Kanamori, T., Iwamoto, E., Muto, T., Tsukamoto, S., Takeda, Y., Ohwada, C., Misawa, S., Ikeda, J., Sanada, M., Kuwabara, S., Suzuki, Y., Sakaida, E., Nakaseko, C., Iwama, A. 2022

    Abstract

    POEMS syndrome is a rare monoclonal plasma cell disorder with unique symptoms distinct from other plasma cell neoplasms, including high serum VEGF levels. Since the prospective isolation of POEMS clones has not yet been successful, their real nature remains unclear. We herein performed the single-cell RNA sequencing of bone marrow plasma cells from patients with POEMS syndrome and identified POEMS clones that had immunoglobulin lambda light chain (IGL) sequences (IGLV1-36, 40, 44, and 47) with amino acid changes specific to POEMS syndrome. The proportions of POEMS clones in plasma cells were markedly smaller (median: 12.9%) than in multiple myeloma (MM) (96-100%) and monoclonal gammopathy of undetermined significance (MGUS) patients (57-81%). Single-cell transcriptomes revealed that POEMS clones were CD19-negative, CD138-positive, and MHC class II-low, which allowed for their prospective isolation. POEMS clones expressed significantly lower levels of c-MYC and CCND1 than MM, accounting for their small size. VEGF mRNA was not up-regulated in POEMS clones, directly indicating that VEGF is not produced by POEMS clones. These results reveal unique features of POEMS clones and enhance our understanding of the pathogenesis of POEMS syndrome.

    View details for DOI 10.1172/jci.insight.151482

    View details for PubMedID 36129760